Skip to main content

Branded

  • FDA approves Shire’s Cuvitru

    LEXINGTON, Mass. — The Food and Drug Administration has approved Shire’s latest treatment Cuvitru (immune globulin subcutaneous (human) 20% solution). The drug is indicated to treat adults and pediatric patients ages two years and older with primary immunodeficiency, a group of more than 300 genetic disorders in which a part of the immune system functions improperly or is missing. 
     

  • Allergan to acquire Vitae Pharmaceuticals

    DUBLIN and FORT WASHINGTON, Pa. — Allergan will be expanding its dermatology pipeline with its plan to acquire Vitae Pharmaceuticals. The acquisition, which was announced Wednesday and has been approved by the boards of both companies, will see the Allergan paying about $631 million in cash for the clinical-stage biotechnology company. 
     

  • Merck Manual professional app update makes mobile reference guide free

    KENILWORTH, N.J. — A new update to the mobile app for the Merck Manual for Healthcare Professionals is broadening access to the reference guide. Merck announced Thursday that with the latest update, the app is entirely redesigned and free. Once the app is downloaded, its content is saved offline so it can be accessed with or without an Internet connection. 
     

  • Express Scripts rolls out value program around inflammatory conditions

  • Upsher-Smith launches savings, support program for Qudexy XR

    MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Thursday announced a new savings and support program for its anti-epileptic drug Qudexy XR, called “It’s That Simple.” The program makes the drug available to eligible patients for a $0 copay. 
     

  • Flu shot now available across Wegmans

    ROCHESTER, N.Y. – The influenza vaccine for the 2016-2017 flu season is now available at all Wegmans Food Markets locations, the supermarket chain announced Thursday.

    “By offering the flu vaccination in our pharmacies, we’re making it easy for our customers to protect themselves from the seasonal flu, while also improving immunization rates in the communities we serve,” stated Katie Niles, Wegmans pharmacist and pharmacy clinical wellness services manager.
     

  • BIO rolls out ‘Innovation Saves’ ad

  • Allergan expands eye care pipeline with acquisition

    DUBLIN and ANN ARBOR, Mich. — Allergan announced Tuesday that it had acquired substantially all of the assets of RetroSense Therapeutics, a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision for patients with blindness. The acquisition saw Allergan pay RetroSense a $60 million upfront payment, with the promise of potential regulatory and commercialization milestone payments for the company’s lead development program, RST-001 — a potential therapy for retinitis pigmentosa. 
     
X
This ad will auto-close in 10 seconds